LL-37

LL-37 is the only human cathelicidin, a small protein (peptide) that the body uses as part of its first-line defense against infection Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. It is released by neutrophils (a type of white blood cell) and cells that line surfaces like the skin, lungs, and gut The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Once released, it can kill a wide range of microbes directly by damaging their outer membranes, but it also acts as a signal that calls in other immune cells and encourages damaged tissue to repair Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells+1.

Research has looked at LL-37 for infected wounds, tissue repair, antimicrobial dressings, and as a way to study how the body balances inflammation and healing. Most of the evidence comes from human observational studies and animal models, not from large clinical trials Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis+2.

LL-37 works in two main ways: it directly attacks microbes, and it sends signals to host cells.

Direct attack on microbes: LL-37 is positively charged, which lets it stick to the negatively charged surfaces of bacteria, viruses, and fungi. It then inserts itself into the microbial membrane, creating holes that cause the microbe to leak and die Structures of Human Host Defense Cathelicidin LL-37 and Its Smallest Antimicrobial Peptide KR-12 in Lipid Micelles+1. This membrane disruption happens quickly and works against many different pathogens Interaction of LL-37 human cathelicidin peptide with a model microbial-like lipid membrane+1.

Signaling the immune system: LL-37 also binds to specific receptors on human cells, especially FPRL1 (a receptor that guides cell movement) and P2X7 (a channel that can trigger inflammation and cell cleanup). Through these receptors, LL-37 attracts neutrophils, monocytes, and T cells to the site of infection Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells. It also helps these neutrophils live longer by preventing them from dying off too soon An Antimicrobial Cathelicidin Peptide, Human CAP18/LL-37, Suppresses Neutrophil Apoptosis via the Activation of Formyl-Peptide Receptor-Like 1 and P2X7.

Triggering cell cleanup and repair: In skin cells, LL-37 turns on a process called autophagy, which is like a cellular housekeeping system that clears out damaged parts and strengthens the cell's barrier. This autophagy helps wounds heal and keeps the skin's protective layer intact Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X₇, Mechanistic Target of Rapamycin, and MAPK Pathways+1. However, the effect is not always beneficial. At high concentrations or in certain tissues, LL-37 can be too aggressive, damaging host cells or causing unwanted inflammation Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity+1.

Research has documented several effects of LL-37, though most findings come from laboratory, animal, or observational human studies.

Antimicrobial activity: LL-37 can kill a broad range of bacteria in lab tests, including drug-resistant strains like MRSA Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model+1. It also has activity against some viruses, blocking their entry into cells Human cathelicidin peptide LL‐37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections+1. However, in the body, its effectiveness can be reduced by proteins in blood, mucus, or enzymes from bacteria The Potential of Human Recombinant Cathelicidin LL-37 in the Treatment of Infections+1.

Wound healing: In animal models, applying LL-37 to wounds sped up closure, increased new blood vessel growth, and improved the quality of the healed tissue. These benefits were seen in normal wounds and infected wounds alike Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model+1.

Immune modulation: LL-37 helps shape the immune response. It can attract immune cells to an infection, help them live longer, and enhance their germ-killing actions Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells+1. In some situations, it also calms excessive inflammation, such as during sepsis (a severe systemic infection), by dampening harmful overreactions Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model.

Barrier protection: In the gut, LL-37 can help maintain the intestinal lining during stress, preventing leakiness Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke. Yet in other studies, direct exposure to LL-37 made intestinal cells more permeable, so the effect depends heavily on dose and context Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity.

Biomarker roles: LL-37 levels are often higher in people with active infections or inflammatory conditions like gum disease, but interpreting these levels is complex. For example, smoking can lower LL-37 even in the presence of periodontitis Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis+1.

Research protocols for LL-37 vary widely by the target tissue and the goal. Most are preclinical, using animal models or laboratory experiments. There are no standardized human dosing guidelines.

Topical wound protocols: The most studied approach is direct application to wounds. Mouse studies have used a single 20 microgram application of LL-37 to each wound, either as a solution or embedded in a hydrogel for slow release. This was done for 11 to 21 days, with improvements seen in re-epithelialization, collagen organization, and new blood vessel formation Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model+1.

Systemic infection protocols: For systemic effects, researchers have given LL-37 by intravenous or subcutaneous injection in animal models. One pharmacokinetic study used a single 20-microgram dose in mice, finding that the peptide cleared from blood rapidly, with intravenous routes handled mostly by the liver and subcutaneous routes by the kidneys The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface.

Lung delivery: For respiratory infections, inhalation of LL-37 loaded into lipid nanoparticles has been tested. This formulation improved mucus penetration and reduced the concentration needed to kill biofilm-protected bacteria compared to free peptide Engineered lipid nanoparticles loaded with LL-37 peptide as inhalable drug delivery carriers for the treatment of bacterial infections.

Practitioner consensus describes topical gels at 0.1 to 1 milligram per milliliter applied one to two times daily for 7 to 21 days. Subcutaneous doses of 50 to 200 micrograms once daily for 5 to 14 days are sometimes reported, but these are not validated by controlled trials.

LL-37's interactions are largely theoretical because there are no formal human drug interaction studies. Most knowledge comes from understanding how LL-37 works.

With other drugs:

• Corticosteroids: High-dose steroids might blunt the immune-recruiting effects of LL-37, which could reduce its benefit when used for infection or wound healing Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model.
• NSAIDs: These anti-inflammatory drugs might reduce some of the signaling effects of LL-37 in airways, since LL-37 can increase COX-2-dependent inflammation LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells.
• Antibiotics: LL-37 can work together with certain antibiotics like amoxicillin/clavulanate against staph bacteria in lab tests, but human data are lacking Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.
• P2X7 or FPRL1-targeting drugs: These could theoretically interfere with LL-37's immune signaling, as those are key receptors Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells+1.

With supplements:

• Vitamin D: Vitamin D increases the body's own production of LL-37. Taking vitamin D alongside LL-37 might add to the overall effect, which could be good for immunity but might also increase inflammatory responses in sensitive individuals Vitamin D and antimicrobial peptides in skin health and disease: Mechanisms and therapeutic potential+1.
• Probiotics: Some probiotics can stimulate the body's own antimicrobial peptides, which may complement LL-37 in gut or mucosal research Crosstalk Between Probiotics and Host Immunity: Antimicrobial Peptides-Mediated Health Benefits.
• Anti-inflammatory supplements (fish oil, curcumin): These might dampen some of LL-37's pro-inflammatory actions, which could be helpful or counterproductive depending on the goal LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells.

LL-37 is sometimes combined with other peptides in research settings, though formal combination studies are rare.

With defensins (HNP-1): LL-37 can form cooperative complexes with another human antimicrobial peptide called HNP-1. In lab studies, this pairing helped neutralize toxicity and may mimic the natural mix of defense molecules found in the body Aggregation-State Dynamics Drive Double Cooperativity Between Antimicrobial Peptides LL-37 and HNP1+1.

With repair peptides (BPC-157, TB-500, GHK-Cu): No direct studies exist, but theoretically, combining LL-37's antimicrobial and immune-signaling actions with peptides that promote tissue repair could benefit wound healing. However, too much immune activation or new blood vessel growth could be problematic in already inflamed tissue Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model+1.

With other membrane-active peptides: Stacking multiple peptides that disrupt membranes might increase antimicrobial power but also raises the risk of harming host cells at higher concentrations. Keeping local doses conservative is recommended The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulator+1.

Because LL-37 has complex, context-dependent effects, combinations are best tested with careful monitoring, especially in tissues prone to excessive inflammation like the skin, gut, or lungs.

LL-37 is not approved by the FDA or any other major regulatory agency as a drug for any condition. It is considered an investigational compound. All research to date is preclinical or observational; no Phase 3 trials or marketing applications have been completed The Potential of Human Recombinant Cathelicidin LL-37 in the Treatment of Infections+1.

In the United States, LL-37 is not listed as a controlled substance. However, selling it for human use would be unlawful without FDA approval. Products are often sold as research chemicals, but regulatory agencies could take action if claims are made about treating diseases.

Internationally, there is no approval from the EMA (Europe), MHRA (UK), or TGA (Australia). Import rules vary by country, and unapproved peptides may be seized by customs.

Regarding sports: LL-37 is not explicitly named on the World Anti-Doping Agency (WADA) Prohibited List. However, because it is a peptide that can influence immune function and potentially tissue repair, athletes should consider it a gray area. Gene therapy or advanced delivery methods using LL-37 could fall under prohibited categories. Competitive athletes are advised to check with their governing body before use The roles of cathelicidin LL-37 in immune defences and novel clinical applications.

LL-37 is a natural part of the human immune system, but giving it from an outside source has risks, especially at higher doses or in sensitive tissues.

Common effects: The most likely issue is local irritation where it is applied, such as redness, itching, or burning on the skin. This is because LL-37 can trigger inflammatory signals in skin cells Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X₇, Mechanistic Target of Rapamycin, and MAPK Pathways+1. In lab tests, LL-37 can be toxic to human cells at concentrations above about 1-10 micromolar, which overlaps with levels used for antimicrobial effects Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.

Gut effects: LL-37 can disrupt the tight seals between intestinal cells, potentially making the gut leakier. This is a key concern for any oral or rectal use, despite some animal data showing gut protection in specific injury models Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity+1.

Lung effects: Inhaled LL-37 can increase inflammatory chemicals and attract neutrophils to the airways, which might worsen conditions like asthma or COPD LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells+1.

Cardiovascular risks: LL-37 has been linked to processes that promote hardening of the arteries, including encouraging endothelial cells to transform in ways that could contribute to plaque buildup Human cathelicidin peptide LL-37 induces endothelial-to-mesenchymal transition+1. These effects are theoretical but caution against use in people with heart disease.

Autoimmune risks: LL-37 can bind to self-DNA, which can overstimulate the immune system and is associated with autoimmune diseases like psoriasis and lupus Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections+1. Anyone with a history of these conditions should avoid LL-37.

Contraindications: Do not use if you have active autoimmune disease, severe gut inflammation, unstable heart disease, or a history of hypersensitivity reactions. Pregnancy, breastfeeding, and cancer are also situations where the risks are unknown and use is not recommended.

Overall, LL-37 is best suited for local, short-term applications in controlled research settings. Long-term or systemic use is not supported by safety data.